Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
MilliporeSigma has formed a strategic alliance with Baylor College of Medicine for Vaccine Development to advance vaccine research and development for neglected and emerging infections.
read more
Wednesday, December 07, 2016
MilliporeSigma will provide its Provantage® End-to-End services to Acticor Biotech SAS for accelerated development and manufacturing of Acticor's antibody fragment used for the primary treatment of ischemic stroke.
read more
Tuesday, February 18, 2020
MilliporeSigma has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits.
read more
MilliporeSigma has announced an expansion of its Carlsbad, California facility to meet growing demand for viral and gene therapy products.
read more
Wednesday, October 15, 2025
MilliporeSigma announced that the Life Science business of Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences, a provider of contract development and manufacturing, preclinical...
read more
MilliporeSigma and The Jenner Institute announced The Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
read more
Thursday, December 21, 2017
MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio, for its use in gene therapies.
read more
MilliporeSigma is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges, helping accelerate ...
read more
MilliporeSigma has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, Wisconsin, USA. This new US$65 million, 70,000 square foot facility, officially ...
read more
Wednesday, October 11, 2017
MilliporeSigma today officially opened its new Life Science Center in Burlington, Massachusetts.
read more
Wednesday, October 09, 2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA. Biosafety testing and analytical development are fundamental ...
read more
Friday, February 16, 2018
MilliporeSigma today introduced Viresolve Barrier capsule filters to reduce the risk of bioreactor contamination.
read more
Wednesday, January 18, 2017
MilliporeSigma has introduced CAN MultiFlow™ screening services to more accurately predict genotoxic and mode of action* properties of substances, ingredients and drug compounds. Offered through its BioReliance® testing facilities, MilliporeSigma ...
read more
Tuesday, October 08, 2019
MilliporeSigma has introduced its ADC Express services for the rapid production of ADCs, which can reduce the time needed to produce development grade constructs for target molecule identification.
read more
MilliporeSigma announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative.
read more